ClinicalTrials.gg
TerminatedNCT01356992VECORUpdated Jun 18, 2015

Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation

A Phase 3 interventional study of Enoxaparin in Non ST Segment Elevation Myocardial Infarction and Unstable Angina, sponsored by Eurofarma Laboratorios S.A.. Terminated at 5 sites in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-18.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Why this study was terminated
Change in strategy regarding the product by the company

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Angina, Unstable with a site in Brazil — 2 open to participants now, 2 under way, none of them phase 3. Angina, Unstable · Brazil.

Enrollment
11th of 11
62 · median 2,753
Started
2012
the only one that year
Phase 3
6 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Eurofarma Laboratorios S.A.

Among the 13 studies in Angina, Unstable with a site in Brazil, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2012, is one of 6 in phase 3, and was the 8th registered.

Angina, Unstable

330 studies on the registry are indexed under Angina, Unstable; 42 are open to participants now.

Browse Angina, Unstable studies →

Open to participants now

2 of the 13 studies in Angina, Unstable with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 34 Angina, Unstable studies recruiting now, 29 (85%) set no upper age limit and 3 (9%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Angina, Unstable with a site in Brazil, or all of them as a file.
02

Study summary

This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI. The main justification is the search for scientific evidence to prove the Versa® effectiveness for this new therapeutic indication, since it is a product with potential for reducing costs, with effectiveness and safety comparable to the reference drug.

Read the detailed description

To be included in this study, the eligible patients must meet all criteria below:

IC signature; The research subject must agree about following all instructions and perform the procedures and study visits; Men and women over the age of 18 and below the age of 75; History of angina of rest with a minimum duration of 20 minutes in the last 24 hours at the beginning and at least for 10 days.

Patient Randomization up to 6 hours after the arrival at the emergency sector.

Evidence of NSTEMI or unstable angina due to one or more of the following criteria:

  1. Dynamic alterations on the T-wave (ST-segment depression or elevation > 1 mm, and/or T-wave inversions which are solved at least partially when the symptoms are relieved) or 2. Unevenly ST-segment (depression or elevation) in a transitional way under continuous derivations (V1+V2 or V3+V4 or V5+V6 or D1+AVL or D2+D3+AVF) or 3. Biochemical alteration on the myocardial necrosis markers (CKMB mass, troponin T or I and CPK), with the appearance of enzymatic curve, characterizing myocardial injury or 5. Pulmonary Edema; or 6. Angina associated to murmur of mitral regurgitation; or 7. Angina with heart sound to cardiac auscultation or throes; or 8. Angina with hypotension;

The patients who meet anyone of the criteria below will not be eligible for the study:

12-derivation-ECG with persistent ST-segment elevation; Diagnosis of angina by secondary cause (e.g., anemia, fever, hypovolemia, dehydration, use of cocaine); Use of non-fractionated heparin or low-molecular weight heparin in the prior 48 to the randomization; Concomitant diseases, such as severe renal failure (creatinine clearance lower than 30ml/min.) and hepatic, or other significant comorbidities under investigator judgment; Recent hemorrhagic cerebrovascular accident (last 12 months); Patient scheduled for cardiac surgery of myocardial revascularization; Use of drugs, alcohol abuse; Pregnancy or lactation; Recent neurosurgery or ophthalmic surgery (last 3 months); History or diagnosis of coagulopathy; Medical record containing allergy, hypersensibility or intolerance to any of the drug components to be used on this study, which is judged as clinically significant in the main investigator's opinion; Recent participation (last 12 months) in a clinical study.

03

Conditions studied

  • Non ST Segment Elevation Myocardial Infarction
  • Unstable Angina

Browse trials for

Keywords

  • non-inferiority phase III study
  • Low-Molecular Weight Heparin
  • Versa® (enoxaparin - Eurofarma)
  • Clexane® (enoxaparin - Sanofi-Aventis)
  • Acute coronary syndrome without ST-segment elevation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ICF signature;
  • The research subject must agree about following all instructions and perform the procedures and study visits;
  • Men and women over the age of 18 and below the age of 75;
  • History of angina of rest with a minimum duration of 20 minutes in the last 24 hours at the beginning and at least for 10 days.
  • Patient Randomization up to 6 hours after the arrival at the emergency sector.
  • Evidence of NSTEMI or unstable angina due to one or more of the following criteria:

    1. Dynamic alterations on the T-wave (ST-segment depression or elevation > 1 mm, and/or T-wave inversions which are solved at least partially when the symptoms are relieved) or 2. Unevenly ST-segment (depression or elevation) in a transitional way under continuous derivations (V1+V2 or V3+V4 or V5+V6 or D1+AVL or D2+D3+AVF) or 3. Biochemical alteration on the myocardial necrosis markers (CKMB mass, troponin T or I and CPK), with the appearance of enzymatic curve, characterizing myocardial injury or 5. Pulmonary Edema; or 6. Angina associated to murmur of mitral regurgitation; or 7. Angina with heart sound to cardiac auscultation or throes; or 8. Angina with hypotension;

Exclusion criteria

Exclusion Criteria:

  • 12-derivation- with persistent ST-segment elevation;
  • Diagnosis of angina by secondary cause (e.g., anemia, fever, hypovolemia, dehydration, use of cocaine);
  • Use of non-fractionated heparin or low-molecular weight heparin in the prior 48 to the randomization;
  • Concomitant diseases, such as severe renal failure ( lower than 30ml/min.) and hepatic, or other significant comorbidities under investigator judgment;
  • Recent hemorrhagic cerebrovascular accident (last 12 months);
  • Patient scheduled for cardiac surgery of myocardial revascularization;
  • Use of drugs, alcohol abuse;
  • Pregnancy or lactation;
  • Recent neurosurgery or ophthalmic surgery (last 3 months);
  • History or diagnosis of coagulopathy;
  • Medical record containing allergy, hypersensibility or intolerance to any of the drug components to be used on this study, which is judged as in the main investigator's opinion;
  • Recent participation (last 12 months) in a clinical study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    Clexane® (enoxaparin - Sanofi)

    Drug: Enoxaparin

  • Experimental
    Versa® (enoxaparin - Eurofarma)

    Drug: Enoxaparin

Interventions

  • Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.

06

What researchers measure

Primary outcomes

  1. Frequency of death and infarction within 30 days after the admission in emergency

    The study primary objective aims at evaluating the enoparaxin sodium (Eurofarma) effectiveness and safety on the treatment of patients with NSTE-ACS and high-risk ones, regarding the Sanofi-Aventis enoxaparin sodium. The primary endpoint will be the frequency of death and infarction within 30 days after the admission in emergency.

    Time frame: 30 days after the admission in emergency

Secondary outcomes

  1. Comparing the effectiveness and safety of the two formulations in patients with NSTE-ACS and high-risk ones

    The secondary endpoints considered for the study are: Negative endpoints associated to ACS (shock, pulmonary congestion, arrhythmias, congestive heart failure, hemodynamic instability and reinfarction) during 30 days after the beginning of the treatment. Frequency of coronary angioplasty or surgical revascularization procedures; Rate of major bleeding during hospitalization according to TIMI criteria ; Incidence of hemotransfusion in the 30 days after the inclusion on the study.

    Time frame: 30 days after the admission in emergency

07

Study locations

5 sites
  • Salvador, Bahia, Brazil
  • Belo Horizonte, Minas Gerais, Brazil
  • Porto Alegre, Rio Grande do Sul, Brazil
  • São Jose do Rio Preto, São Paulo, Brazil
  • São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2011
First posted
May 20, 2011
Start
Jul 2012
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Jun 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01356992
Responsible party
Sponsor
First posted
May 20, 2011
Start date
Jul 2012
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Jun 18, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion